Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology Atriva Therapeutics and Canadian Biocure Technologies, Inc. entered into an exclusive letter agreement for a reverse takeover transaction. Upon successful completion of the transaction, the...

Atriva Therapeutics将进行II期研究以开发用于新冠肺炎患者治疗的ATR-002 临床前研究表明ATR-002的作用方式可抑制新冠病毒（新冠病毒）的传播并预防细胞因子风暴Atriva的这一首要候选药品是专门治疗由RNA病毒（如流感病毒和新冠病毒）所引发呼吸道感染的唯一一种宿主靶向抗病毒药物由于具有双重抗病毒和免疫功效，小型分子有可能阻止新冠肺炎住院患者的病情恶化进入危险期，因而具备在目前全球疫情中发挥巨大作用的潜力 德国图宾根, May 29, 2020 (GLOBE...

Atriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase II Study ATR-002 mode of action inhibits SARS-CoV-2 viral propagation and prevents the cytokine storm as demonstrated in preclinical studiesAtriva’s lead product candidate is the only host-targeted antiviral...